Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.

Female using Rogaine foam for hair loss had scalp punch biopsy, diagnosed with Androgenetic Alopecia (AGA). Doctor recommended starting Spironolactone 50mg.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

User experienced hair loss due to anorexia and stress, leading to a difficult journey with wigs and self-esteem. Hair regrowth occurred with spironolactone, but recent hair loss returned, causing uncertainty and emotional struggles.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

A 24-year-old woman being diagnosed with androgenic alopecia (AGA) who is scared and confused about her hair loss, and the treatment options of Minoxidil, finasteride, RU58841, spironolactone, and possibly a biopsy.

Hair loss can begin in early adolescence and cause mental anguish. Treatments mentioned include eating cruciferous vegetables, engaging in physical activity, and maintaining scalp hygiene.

A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.

Elevated bile acids can inhibit the enzyme AKR1C2, leading to increased DHT levels, which may accelerate hair loss in those predisposed to androgenetic alopecia. Treatments mentioned include topical minoxidil and finasteride.

Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to be overharvested without noticeable hair loss. The conversation questions if this method is practiced in clinics or if it's theoretical, and whether it relates to hair cloning or multiplication.

Stopping finasteride and minoxidil can cause significant hair shedding, so they should be continued indefinitely. Concerns about finasteride affecting fertility or causing birth defects are mostly unfounded, but some stop for personal reasons.

The user experienced initial improvement in hair loss with oral finasteride and minoxidil but later faced increased shedding and thinning. They switched to dutasteride, hoping for better results, while continuing topical minoxidil.

The conversation discusses hair shedding while using finasteride for hair loss treatment. The user is concerned about whether the shedding is a normal part of the treatment process.

A female user is experiencing hair loss from the root and dead ends, likely due to post-partum effects, ankylosing spondylitis, and low iron. She seeks advice on improving hair health before going fully blonde.

Switching from Kirkland minoxidil foam to a topical finasteride/minoxidil solution can cause significant hair shedding. The user also uses dutasteride, RU58841, and pyrilutamide in their treatment regimen.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

Stopping finasteride due to side effects and family planning can lead to temporary increased hair shedding, which may stabilize over time. Consider topical treatments or a lower dose after addressing current concerns.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

The user experienced significant hair shedding after pausing their hair care regimen, which included finasteride, micro-needling, Nizoral shampoo, vitamin D, essential oils, melatonin, caffeine, exercise, and protein intake. They are concerned if the shedding is due to the break in their routine or a normal phase of finasteride use.

Hair loss treatments and the user's plan to start using Pyrilutamide, a combination of Minoxidil and Finasteride.

The user is pleased with their hair transplant results but is concerned about the vertex area. They use Minoxidil and finasteride daily and had the procedure at a clinic in Athens.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.

Switching from finasteride to dutasteride can cause significant hair shedding if done abruptly. It's recommended to overlap both treatments and gradually taper off finasteride to minimize shedding.

The user experienced significant hair regrowth using topical finasteride and minoxidil but faced a prolonged shedding phase, leading them to increase the finasteride dose and add oral dutasteride. Despite concerns about shedding, they remain hopeful for regrowth and are supplementing with Vitamin D.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

Minoxidil and finasteride may cause different shedding patterns; the user experienced shedding with finasteride which stopped, and is now concerned about potential shedding after starting minoxidil. They have been on finasteride for 3 months, minoxidil for 1 week, and had exosome therapy 1 month ago.